Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview.
Adams
G E
GE
Stratford
I J
IJ
D000477:Alkylating Agents; D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D004357:Drug Synergism; D017341:Etanidazole; D000860:Hypoxia / Q000378:metabolism; D008920:Misonidazole / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D009581:Nitrofurans / Q000378:metabolism / Q000627:therapeutic use*; D009583:Nitrofurazone / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D009593:Nitroimidazoles / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D010084:Oxidation-Reduction; D011838:Radiation-Sensitizing Agents; D013329:Structure-Activity Relationship
D000477:Alkylating Agents; D009581:Nitrofurans; D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D017341:Etanidazole; C033815:pimonidazole; D008920:Misonidazole; D009583:Nitrofurazone